www.asiatimes.com.au News and Views from Asia Pacific
MUMBAI & TOKYO: Sun Pharma announced the initiation of a phased transfer of manufacturing & marketing rights in Japan for the 14 long-listed/established prescription brands acquired from Novartis. These 14 prescription brands acquired by the company earlier this year will be transferred from Novartis Pharma K.K. to Sun Pharma’s subsidiary …
Read More »Tag Archives: Sun Pharma
Sun Pharma announces closure of merger deal with Ranbaxy
[vc_row][vc_column width=”1/1″][vc_column_text]· 100% compliance, enhancing R&D productivity & strong business growth are the key priorities · Announces Management Leadership Team to lead combined entity’s next growth phase · Plans strong team of Functional Leaders drawing best of Sun Pharma & Ranbaxy Mumbai, India: Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: …
Read More »Sun Pharma to buy GSK’s Opiates business in Australia
MELBOURNE[AUSTRALIA] and MUMBAI[INDIA]: GlaxoSmithKline (GSK) and Sun Pharmaceutical Industries announced that their respective wholly owned subsidiaries have reached an agreement related to GSK’s Opiates business in Australia. The current GSK Opiates business including related manufacturing sites in Latrobe (Tasmania) and Port Fairy (Victoria) and its portfolio of opiates products along …
Read More »CCI Approves the Proposed Merger Between Sun Pharma and Ranbaxy
Mumbai and Gurgaon, India: Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) and Ranbaxy Laboratories Ltd (Reuters: RANB.BO, Bloomberg: RBXY IN, NSE: RANBAXY, BSE: 500359) today announced that they have received the order of the Competition Commission of India (“CCI”) dated December 5, 2014 (“Order”) …
Read More »Sun Pharma and Merck & Co. enter into Agreement for Tildrakizumab
WHITEHOUSE STATION, N.J., and MUMBAI, INDIA: Merck & Co., Inc., known as MSD outside the United States and Canada, and Sun Pharmaceutical Industries Ltd. through their respective subsidiaries, today announced an exclusive worldwide licensing agreement for Merck’s investigational therapeutic antibody candidate, tildrakizumab, which is currently being evaluated in Phase 3 …
Read More »